Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q1 2024 Earnings Call Transcript

If it’s 0.67 or less, then it might take more time. So, 0.67 is enough to hit it, but you need to have enough fractures. So that’s the other. Those two variables are synergistic and how they’re impact things. So, we wouldn’t we couldn’t say for sure. I think trying to handicap whether the first one is going to hit, it’s stringent. I think it’s a relatively lower possibility of hitting. But we wanted to open the door in case fractures were high and the reduction was high and we were already off scale, they wouldn’t keep going with those kids on placebo. And you can imagine, there’s people, children. So continuing placebo when they’re when you’ve already gone way past what’s required, I think that’s smart. So, and better for them the right thing to do.

Thank you.

Operator: Thank you. I’m showing no further questions in the queue. I would now like to turn the call back over to Joshua for closing remarks.

Joshua Higa: Thank you. This concludes today’s call. If there are additional questions, please contact us by phone or at ir@ultragenyx.com. Thank you for joining us.

Operator: Ladies and gentlemen, this concludes today’s conference call. [Operator Closing Remarks].